Launch of the first dengue vaccine in Malaysia

PETALING JAYA – Malaysia’s defense against dengue fever was strengthened by the launch of its first vaccine against this disease.

Takeda Malaysia launched its dengue tetravalent (live attenuated), Qdenga vaccine on Tuesday, June 11.

The vaccine approved by the Drug Control Authority is intended to protect against four serotypes of dengue virus.

Two doses are required every three months and it can be given to anyone aged 4 and up.

Takeda’s Malaysia & Singapore Country General Manager Dr Lynette MOEY said that the impact of dengue can not be overstated.

She said that Asia was bearing a large burden of dengue in the world.

The World Health Organization (WHO), has identified dengue as a top 10 threat to global health. This underscores the urgency of our collective effort to tackle this pressing issue.

She added, “In light of the ongoing impact of recent pandemics, we are acutely conscious of the need to face health threats with innovation and resilience.”

Dr Moey stated that the vaccine would be available in private hospitals and general practitioners clinics.

We cannot reveal the price. “The healthcare facility will determine their own price”, she replied when asked about the price of the vaccine.

She stated that it would be “extremely √©quitable” in terms affordability.

Dr Moey stated that the company would be willing to work with the Health Ministry to bring the vaccine into the public healthcare system.

She stated that clinical trials showed the vaccine prevented 80.2% symptomatic cases of dengue 12 months after vaccination.

She added that after a four-and-a half year period, the vaccine was 84.1% effective against hospitalisations and 61.2% effective against symptomatic conditions.

The vaccine is approved in over 30 countries including the European Union (EU), the United Kingdom (UK), Brazil, Argentina and Indonesia, Thailand, Vietnam.

Dengue cases increased by 86.3% in Malaysia in the last year compared to 2022.

In the first three months of this year, there were 41,565 reported cases in the United States, and 28 deaths.

Related Articles